Multiplex Assay Kit for Procollagen III C-Terminal Propeptide (PIIICP) ,etc. by FLIA (Flow Luminescence Immunoassay) 
P3CP; C-Propeptide Of Type III Procollagen; Procollagen III Carboxy Terminal Propeptide
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 393.00 US$ 408.00 US$ 431.00 US$ 461.00 US$ 491.00 US$ 537.00 US$ 605.00 US$ 756.00
- Quantity
Overview
Properties
- Product No.LMA963Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryMetabolic pathwayBone metabolism
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Procollagen III C-Terminal Propeptide (PIIICP) and the recovery rates were calculated by comparing the measured value to the expected amount of Procollagen III C-Terminal Propeptide (PIIICP) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 78-94 | 88 |
| EDTA plasma(n=5) | 93-102 | 97 |
| heparin plasma(n=5) | 81-91 | 85 |
| sodium citrate plasma(n=5) | 91-98 | 94 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Procollagen III C-Terminal Propeptide (PIIICP) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Procollagen III C-Terminal Propeptide (PIIICP) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Procollagen III C-Terminal Propeptide (PIIICP) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 79-101% | 79-98% | 92-101% | 91-99% |
| EDTA plasma(n=5) | 97-105% | 94-102% | 98-105% | 84-96% |
| heparin plasma(n=5) | 92-101% | 82-90% | 81-92% | 97-104% |
| sodium citrate plasma(n=5) | 79-96% | 93-101% | 89-98% | 82-101% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:PIIICP) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 100μL standard or sample to each well, add 10μL magnetic beads, and incubate 120 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60 minutes protect from light at 25°C on shaker;
5. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
6. Wash plate once on magnetic frame;
7. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.
Test principle
Anti-Procollagen III C-Terminal Propeptide (PIIICP) antibody was coated on the surface of magnetic beads, to make solid phase carrier. Standard or sample were added to the magnetic beads, respectively, in which Procollagen III C-Terminal Propeptide (PIIICP) was bound to the antibody connected to the solid phase carrier, and then biotinylated anti-Procollagen III C-Terminal Propeptide (PIIICP) antibodies were added. PE-labeled avidin was added. There is a positive correlation between the concentration of Procollagen III C-Terminal Propeptide (PIIICP) in the sample and corresponding value of MFI (Median Fluorescence Intensity).
Giveaways
Increment services
Citations
- Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathypubmed:27516211
- Left ventricular reverse remodeling is not related to biopsy-detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRRpubmed:28004175
- Endothelial‑to‑mesenchymal transition in human idiopathic dilated cardiomyopathypubmed:29115553
- Left ventricular reverse remodeling is not related to biopsy‑detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR10.1007/s00380-016-0930-y
- 12-month patterns of serum markers of collagen synthesis, transforming growth factor and connective tissue growth factor are similar in new-onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis.pubmed:28460256
- Prognostic value of fibrosis-related markers in dilated cardiomyopathy: A link between osteopontin and cardiovascular events.pubmed:29120858
- Extracellular matrix collagen biomarkers levels in patients with chronic thromboembolic pulmonary hypertensionPubmed: 33175289